May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Combined Analysis of CORRECT and CONCUR Confirms Survival Benefit of Regorafenib
July 7th 2015The survival benefit observed with regorafenib over placebo in Asian patients who had been previously treated for mCRC in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.
Read More
Low Expression of Two Genes Could Predict Response to Frontline Oxaliplatin in mCRC
June 23rd 2015Low expression of the genes ERCC1 and TS was associated with substantial improvements in overall survival following front-line treatment with an oxaliplatin-based chemotherapy regimen for patient with metastatic colorectal cancer.
Read More
New Review Highlights Tips for Managing Regorafenib-Related HFSR
June 16th 2015Hand-foot skin reaction represents one of the most troublesome adverse events associated with the multikinase inhibitor regorafenib, yet most treating physicians are unfamiliar with management tactics for this debilitating side effect.
Read More
Internal Radiation Therapy Slows Liver-Disease Progression in mCRC
June 12th 2015The combination of selective internal radiation therapy (SIRT) with first-line chemotherapy showed a 31% reduction in the risk of disease progression within the liver of patients with metastatic colorectal cancer (mCRC) compared with chemotherapy alone.
Read More
Colorectal Tumors Deficient in Mismatch Repair Respond to PD-1 Inhibition
June 5th 2015Patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair experienced high response rates when treated with the programmed cell death protein-1 inhibitor pembrolizumab (Keytruda), according to findings from an ongoing phase II study.
Read More
Liquid Biopsies Detect Minimal Residual Disease in Colorectal Cancer
April 29th 2015Two different types of liquid biopsies—plasma and urine—can detect the number of copies of the KRAS mutation in circulating DNA in patients with colorectal cancer who have resectable liver metastases with near 100% concordance with tissue biopsies, according to a pilot study presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR).
Read More
A Little STING May Enhance the Immune System Against Cancer
April 25th 2015Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Read More